Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
OptimizeRx Corp reported preliminary financial results for the three and twelve months ended December 31, 2023.
- Period
- the three and twelve months ended December 31, 2023
- Result
- preliminary results
Exact text from the filing
On March 28, 2024, the Company held a conference call to discuss preliminary, unaudited results for the fourth quarter.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
OptimizeRx Corp amended Financing Agreement with Blue Torch Finance, LLC valued at Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20 (effective 2024-03-29).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Blue Torch Finance, LLC
- Value
- Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20
- Effective
- 2024-03-29
Exact text from the filing
On March 29, 2024, OptimizeRx Corporation (the “Company”) entered into Amendment No. 1 to the Financing Agreement (the “Amendment”) which amends the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “Financing Agreement”) between the Company, the lenders from time to time party thereto (the “Lenders”) and Blue Torch Finance, LLC, a Delaware limited liability company (“Blue Torch”), as collateral agent and administrative agent for the Lenders.
View on SEC.gov